These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22753075)

  • 21. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome.
    Rahner N; Friedrichs N; Wehner M; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
    Acta Oncol; 2007; 46(6):763-9. PubMed ID: 17653898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
    Long Q; Peng Y; Tang Z; Wu C
    Int J Clin Exp Pathol; 2014; 7(10):7297-303. PubMed ID: 25400828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative diagnosis of Lynch syndrome with DNA mismatch repair immunohistochemistry on a diagnostic biopsy.
    Warrier SK; Trainer AH; Lynch AC; Mitchell C; Hiscock R; Sawyer S; Boussioutas A; Heriot AG
    Dis Colon Rectum; 2011 Dec; 54(12):1480-7. PubMed ID: 22067175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis.
    Hinrichsen I; Brieger A; Trojan J; Zeuzem S; Nilbert M; Plotz G
    Clin Cancer Res; 2013 May; 19(9):2432-41. PubMed ID: 23403630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel.
    O'Regan T; Chau K; Tatton M; Smith T; Parry S; Bissett I
    N Z Med J; 2013 Sep; 126(1382):70-7. PubMed ID: 24154771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
    Clay MR; Allison KH; Folkins AK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multivariate analysis of MLH1 c.1664T>C (p.Leu555Pro) mismatch repair gene variant demonstrates its pathogenicity.
    Farrell MP; Hughes DJ; Drost M; Wallace AJ; Cummins RJ; Fletcher TA; Meany MA; Kay EW; de Wind N; Power DG; Andrews EJ; Green AJ; Gallagher DJ
    Fam Cancer; 2013 Dec; 12(4):741-7. PubMed ID: 23712482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conservation of functional asymmetry in the mammalian MutLα ATPase.
    Johnson JR; Erdeniz N; Nguyen M; Dudley S; Liskay RM
    DNA Repair (Amst); 2010 Nov; 9(11):1209-13. PubMed ID: 20864418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein.
    Ollila S; Sarantaus L; Kariola R; Chan P; Hampel H; Holinski-Feder E; Macrae F; Kohonen-Corish M; Gerdes AM; Peltomäki P; Mangold E; de la Chapelle A; Greenblatt M; Nyström M
    Gastroenterology; 2006 Nov; 131(5):1408-17. PubMed ID: 17101317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
    Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
    Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of eight unclassified missense variants of the MLH1 gene on Lynch syndrome susceptibility.
    Fan Y; Chen J; Wang W; Wu P; Zhi W; Xue B; Zhang W; Wang Y
    Biochem Genet; 2012 Feb; 50(1-2):84-93. PubMed ID: 21952876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defects of DNA mismatch repair in human prostate cancer.
    Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
    Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A CRM1-dependent nuclear export pathway is involved in the regulation of MutLα subcellular localization.
    Brieger A; Adam R; Passmann S; Plotz G; Zeuzem S; Trojan J
    Genes Chromosomes Cancer; 2011 Feb; 50(2):59-70. PubMed ID: 21064154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular basis of HNPCC: mutations of MMR genes.
    Papadopoulos N; Lindblom A
    Hum Mutat; 1997; 10(2):89-99. PubMed ID: 9259192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions.
    Thompson BA; Greenblatt MS; Vallee MP; Herkert JC; Tessereau C; Young EL; Adzhubey IA; Li B; Bell R; Feng B; Mooney SD; Radivojac P; Sunyaev SR; Frebourg T; Hofstra RM; Sijmons RH; Boucher K; Thomas A; Goldgar DE; Spurdle AB; Tavtigian SV
    Hum Mutat; 2013 Jan; 34(1):255-65. PubMed ID: 22949387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing pathogenicity of MLH1 variants by co-expression of human MLH1 and PMS2 genes in yeast.
    Vogelsang M; Comino A; Zupanec N; Hudler P; Komel R
    BMC Cancer; 2009 Oct; 9():382. PubMed ID: 19863800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants.
    Borràs E; Pineda M; Cadiñanos J; Del Valle J; Brieger A; Hinrichsen I; Cabanillas R; Navarro M; Brunet J; Sanjuan X; Musulen E; van der Klift H; Lázaro C; Plotz G; Blanco I; Capellá G
    J Med Genet; 2013 Aug; 50(8):552-63. PubMed ID: 23709753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.